Trials / Enrolling By Invitation
Enrolling By InvitationNCT07420075
Alzheimer's Registry
PPD™ CorEvitas™ International Alzheimer's (ALZ) Drug Safety and Effectiveness Registry
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,000 (estimated)
- Sponsor
- CorEvitas · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The design is an open-ended, prospective, observational, (non-interventional) registry for subjects with mild cognitive impairment (MCI), early symptomatic Alzheimer's disease, Alzheimer's disease, or dementia with clinical suspicion of Alzheimer's disease under the care of a neurologist, psychiatrist, geriatrician or other qualified provider. Longitudinal data are collected from subjects, their care partner(s), and their treating healthcare provider during routine clinical encounters using a structured and standardized data collection method. Approximately 2,000 subjects, with no defined upper limit, across around 75 clinical sites worldwide will be recruited.
Detailed description
The objective of the registry is to create a prospective cohort of Alzheimer's disease subjects to evaluate long-term real-world safety and effectiveness of standard of care treatments for Alzheimer's disease. Data collected through the registry may be used to address a range of research questions and use cases, including but not limited to: Evaluating the effectiveness and safety of commercially available medications for the treatment of Alzheimer's disease, Providing information to support ongoing risk-benefit evaluation by drug manufacturers and regulators, Research related to drug utilization, disease burden, and unmet needs and Supporting post-authorization safety studies to generate evidence related to real world safety of medications used for the treatment of the disease(s) under study
Conditions
Timeline
- Start date
- 2025-11-24
- Primary completion
- 2099-12-31
- Completion
- 2099-12-31
- First posted
- 2026-02-19
- Last updated
- 2026-02-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07420075. Inclusion in this directory is not an endorsement.